236,765 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC purchased a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, HoldingsChannel reports. The firm purchased 236,765 shares of the company’s stock, valued at approximately $4,267,000.

A number of other hedge funds also recently bought and sold shares of the company. New Covenant Trust Company N.A. purchased a new position in Teva Pharmaceutical Industries in the first quarter worth about $28,000. EntryPoint Capital LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at approximately $30,000. UMB Bank n.a. increased its holdings in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $48,000. Finally, Byrne Asset Management LLC purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $18.64 on Tuesday. Teva Pharmaceutical Industries Limited has a 1-year low of $8.55 and a 1-year high of $19.08. The company has a 50-day moving average of $18.03 and a two-hundred day moving average of $17.02. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TEVA shares. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.